Race Oncology (ASX:RAC) to trial Bisantrene on various cancers
- Race Oncology (RAC) has updated the market on its activities for the December 2019 quarter
- The company launched a 5-path clinical strategy for its cancer drug called Bisantrene
- Bisantrene is targeting cancers beyond Acute Myeloid Leukaemia (AML), such as ovarian and breast cancer
Race Oncology (ASX:RAC) to trial Bisantrene on various...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
0.000(0.00%) |
Mkt cap ! $216.0M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1587 | $1.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 39516 | 4 |
View Market Depth
| Last trade - 07.07am 30/04/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable